NCT01183949已完成1 期
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 5
- 主要终点
- To evaluate the clinical efficacy of AT7519M alone or in combination with bortezomib
研究概览
简要总结
The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
详细描述
The clinical study AT7519M/0004 is an open-label multicenter study to investigate the efficacy of AT7519M alone and AT7519M in combination with bortezomib in patients with previously treated multiple myeloma (MM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand the risks of the study and provide signed informed consent
- •Age 18 years or older
- •Relapsed and or Refractory MM
- •Disease progression following at least two systemic treatments for MM
- •Patient must be refractory to the last bortezomib
- •ECOG performance status 0, 1 or 2
排除标准
- •Pregnant or lactating females. Patients of childbearing potential must use appropriate birth control throughout the study
- •Inadequate liver function
- •Renal impairment
- •Neutrophil count <1.0 x 10^9 /litre in the absence of growth factors
- •Platelet count <50 x 10^9 /litre in patients in whom <50% of bone marrow nucleated cells are plasma cells and <30 x 10^9 /litre in patients in whom ≥50 % of bone marrow nucleated cells are plasma cells
- •Hemoglobin <8g/dl in the absence of transfusion
- •Treated corrected calcium >ULN
- •Serum creatine phosphokinase >ULN
- •All previous cytotoxic therapies for MM must have been completed at least four weeks prior to treatment with AT7519M (two weeks for all non-cytotoxic therapy)
- •Patients may be receiving concomitant therapy with biphosphonates and low dose corticosteroids. Bisphosphonates doses should be stable for at least 30 days prior to study drug administration. Corticosteroids doses should be stable for at least 7 days prior to study treatment
- •Prior peripheral stem cell transplant within 12 weeks
- •Evidence of mucosal or internal bleeding and/or platelet transfusion refractory (unable to maintain a platelet count >50 x 10^9 /litre)
- •Ongoing infection requiring treatment
- •Previous radiotherapy within 2 weeks of the start of the study
- •Having previously received treatment with a cyclin-dependent kinase or GSK3beta inhibitor
- •Incomplete recovery from previous radiotherapy other than residual cutaneous effects or stable < Grade 2 gastrointestinal toxicity
- •Prior radiotherapy to the head and neck region for head and neck tumors
- •Previous malignancy, except for non-melanomatous skin carcinomas, in situ carcinomas or malignancies with low risk of recurrence.
- •Any severe or uncontrolled systemic conditions (e.g. systemic infection) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
- •Incomplete recovery from surgery other than stable < Grade 2 toxicity
- •Peripheral neuropathy > Grade 2
- •Abnormal left ventricular ejection fraction (< lower limit of normal for the institution for a patient of that age) on echocardiogram
- •History of an ischemic cardiac event, including myocardial infarction within 3 months of study entry
- •Congestive cardiac failure of ≥ grade 3 severity according to NYHA functional classification
- •Unstable cardiac disease
- •History or presence of bradycardia (≤60bpm), left bundle branch block, heart block, cardiac pacemaker or significant atrial tachyarrhythmias
- •If the patient will receive bortezomib (Velcade) during part C of the study, concurrent treatment with any medication known strongly to inhibit or induce CYP3A4, CYP1A2 and CYP2C19 which cannot be discontinued at least two week prior to treatment with AT7519M (other than corticosteroids)
- •Concurrent treatment with any medication that prolongs QT interval and may induce Torsades de Pointes and which cannot be discontinued at least two weeks prior to treatment with AT7519M
- •Family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy
- •Previous history of drug-induced QTc prolongation
- •Screening 12-lead ECG with measurable QTc interval according to Fridericia's Correction of >450 msecs
- •Screening 12-lead ECG with ST depression >1 mm in 2 or more leads or T wave inversion in 2 or more contiguous leads
- •Prior history of infection with human immunodeficiency virus (HIV), known active hepatitis B or C viruses
- •Diffuse infiltrative pulmonary or pericardial disease
- •Known hypersensitivity to bortezomib, boron or any of the excipients of VelcadeTM
- •Epilepsy or other convulsive disorder requiring active management
- •Serious psychiatric illness, active alcoholism or drug addiction that may hinder or confuse follow up evaluation
研究组 & 干预措施
Treatment
Experimental
Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
干预措施: AT7519M (Drug)
Treatment
Experimental
Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
干预措施: Bortezomib (Drug)
结局指标
主要结局
To evaluate the clinical efficacy of AT7519M alone or in combination with bortezomib
时间窗: Subjects with be followed until disease progression (an average of 4 cycles per subject. i.e an average of 84 days)
Efficacy will be assessed using the International Multiple Myeloma Working Group (IMWG) Response Criteria
次要结局
- Assess the type, incidence and severity of clinically significant treatment emergent adverse events as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) V 4.03(Subjects with be followed until disease progression (an average of 4 cycles per subject, i.e an average of approximately 84 days))
- To define the pharmacokinetic profile of AT7519M and bortezomib when administered alone or in combination with bortezomib(2 cycles (i.e an average of 42 days))
- To identify the maximum tolerated dose (MTD) of AT7519M in combination with bortezomib(Subjects with be followed until disease progression (an average of 4 cycles per subject, i.e an average of approximately 84 days))
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or VorinostatHodgkin's LymphomaLow Grade LymphomaNon-Hodgkin's LymphomaLymphomaDiffuse Large Cell LymphomaMantle Cell LymphomaNCT00791011Amgen33
已完成
1 期
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant PatientsHematopoetic Stem Cell TransplantNCT01926899Indiana University15
终止
1 期
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)Acute Myelogenous LeukemiaMyelogenous LeukemiaTreatment Naive AMLNCT02203773AbbVie212
终止
2 期
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's LymphomaHodgkin DiseaseNCT00148018University of Cologne37
终止
2 期
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom MacroglobulinemiaWaldenström MacroglobulinemiaNCT01536067Roswell Park Cancer Institute3